Summary
Amgen Inc. (AMGN) filed an 8-K on September 20, 2013, to report the entry into a significant material definitive agreement. Specifically, the company entered into a 5-year term loan facility credit agreement for $5.0 billion in senior unsecured term loans. This financing is primarily intended to fund the acquisition of Onyx Pharmaceuticals, Inc. and associated fees and expenses. This substantial debt financing underscores Amgen's commitment to its strategic acquisition of Onyx Pharmaceuticals. Investors should note the terms of the loan, including its maturity, amortization schedule, and interest rate structure, which is tied to the company's debt ratings. The covenants within the agreement, such as limitations on debt and asset sales, will also shape Amgen's financial flexibility moving forward.
Key Highlights
- 1Amgen entered into a $5.0 billion senior unsecured term loan facility credit agreement.
- 2The loan has a 5-year term.
- 3The primary purpose of the loan is to finance the acquisition of Onyx Pharmaceuticals, Inc.
- 4The loan includes quarterly amortization of 2.5% of the principal amount.
- 5Interest rates are variable, based on either the LIBOR rate or a base rate, plus a margin dependent on Amgen's credit rating.
- 6The credit agreement contains customary covenants, including limitations on debt, liens, and affiliate transactions.
- 7Amgen has the right to repay the loans early without penalty.